DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Conditions: Non-Small Cell Lung Cancer; PDL1 Negative Non-Small Cell Lung Cancer (NSCLC) Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Nivolumab; Drug: Ipilimumab Sponsors: University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials